Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis (NCT07039916)
A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Mild to Severe Generalized Myasthenia Gravis
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.
Who can join: Review the eligibility criteria below.
Location: Site Number - 1056 — Huntsville, Alabama
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (88 Sites)
Showing the first 25 of 88 sites.
- Site Number - 1056 — Huntsville, Alabama
- Site Number - 1041 — Mobile, Alabama
- Site Number - 1017 — Phoenix, Arizona
- Site Number - 1025 — Scottsdale, Arizona
- Site Number - 1042 — Tucson, Arizona
- Site Number - 1010 — Carlsbad, California
- Site Number - 1028 — Irvine, California
- Site Number - 1023 — Los Angeles, California
- Site Number - 1029 — Rancho Mirage, California
- Site Number - 1004 — San Francisco, California
- Site Number - 1027 — Fort Collins, Colorado
- Site Number - 1001 — New Haven, Connecticut
- Site Number - 1024 — Washington D.C., District of Columbia
- Site Number - 1006 — Clearwater, Florida
- Site Number - 1037 — Ormond Beach, Florida
- Site Number - 1002 — Port Charlotte, Florida
- Site Number - 1050 — Rockledge, Florida
- Site Number - 1007 — Tampa, Florida
- Site Number - 1014 — Atlanta, Georgia
- Site Number - 1043 — Augusta, Georgia
- Site Number - 1054 — Schaumburg, Illinois
- Site Number - 1022 — Lexington, Kentucky
- Site Number - 1032 — Nicholasville, Kentucky
- Site Number - 1046 — New Orleans, Louisiana
- Site Number - 1049 — Foxborough, Massachusetts
📞 Contact the Study Coordinator
Phone: (800) 797-0414
Email: clinicaltrials@immunovant.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Generalized Myasthenia Gravis
- A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis — Scottsdale, Arizona
- A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis — Scottsdale, Arizona
- Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis — Orange, California
- Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis — Los Angeles, California
- Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis — Phoenix, Arizona
- A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. — Scottsdale, Arizona
Explore by condition: All Generalized Myasthenia Gravis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.